Hippo ERcast September 2024

Intro: Boarding blues

Emergency department boarding degrades throughput, delays care, and pushes sick patients into chairs, hallways, and waiting rooms never designed for full emergency evaluation. The problem is no longer just crowding; it is hospital-wide operational failure tied to left-without-being-seen rates, patient satisfaction, clinician morale, and lost revenue. Emergency Department Boarding Crisis Nonstandard care spaces: Boarding shifts evaluation and treatment out of standard ED rooms into triage chairs, hallways, and waiting areas, where interviews, exams, imaging flow, and timely treatment all become harder. Throughput metric fallout: The visible downstream effects are worse productivity, higher left-without-being-seen rates, and lower patient satisfaction as new ED arrivals compete with admitted boarders for finite staff and beds. Clinician morale injury: Boarding erodes clinician satisfaction because nurses and physicians are forced to care for both admitted and undifferentiated ED patients at once, often with a real sense of institutional disrespect. Hospital-wide financial tension: A boarded-up ED cannot room and evaluate new patients, creating lost emergency revenue while exposing the uncomfortable tradeoff between ED access and higher-margin elective surgical admissions. System-level relief valves: Potential fixes include chest pain and continuity clinics to avoid unnecessary observation stays, plus redistributing boarders to PACU or inpatient hallways. We get into which ideas may actually move the needle in the episode.

Infected Stones: Interpreting Borderline UAs and Admission Decisions

Infected urolithiasis is a sepsis-prone obstructive urinary emergency, not a routine kidney stone visit. Fever is the strongest bedside predictor, urinalysis is often more useful than bloodwork for early suspicion, and obstruction is what turns infection into a mortality problem. Diagnosing Infected Urolithiasis Fever as key predictor: Fever is the strongest clinical clue to an infected stone, and 20-50% of these patients can progress to sepsis or septic shock if obstruction and infection travel together. Borderline UA interpretation: Pyuria above 5 WBCs/hpf and positive leukocyte esterase support infection, but positive nitrites should be treated as infection until proven otherwise. We get into the gray-zone UA nuance in the episode. Symptoms that actually matter: Reported fever, dysuria, chills, frequency, and malodorous urine increase concern for infected urolithiasis, while hematuria, nausea, and vomiting do not reliably separate it from an uncomplicated stone. Contamination and false reassurance: Squamous cells point toward a contaminated specimen worth repeating, and a normal CBC or creatinine does not reliably exclude infection even when the urinalysis is equivocal. Working ED definition: There is no universal ED definition for an infected kidney stone; the practical bedside diagnosis rests on a stone plus convincing urinalysis and clinical infection features while culture is pending. Imaging, Treatment, and Disposition CT imaging advantage: CT is the preferred imaging test when infected urolithiasis is suspected, and IV contrast can better show alternate diagnoses, abscess, and the severity of obstruction for procedural planning. Ultrasound septic screen: Ultrasound is useful when a UTI patient looks septic because hydronephrosis supports obstruction, and pyonephrosis is a particularly dangerous finding with a strong diagnostic signal. Antibiotic first-line choice: Management centers on resuscitation, antibiotics, and urgent urology input, with ceftriaxone as an excellent initial agent before broader gram-negative coverage for sicker or higher-risk patients. Urgent decompression imperative: Infected stones with obstruction need prompt collecting-system drainage because delayed decompression drives AKI and mortality; survival improves when source control happens early. Who can go home: Discharge is limited to patients with smaller non-obstructing stones who are well-appearing, afebrile, able to take oral antibiotics, and able to secure close urology follow-up. We walk through the admission-versus-discharge judgment in the chapter.

Light em up? Radiation use in pregnancy

Diagnostic imaging in pregnancy is usually safer than clinicians and patients fear. ACOG notes that most radiography, CT, and nuclear medicine studies deliver fetal doses far below levels associated with reported fetal harm, while the larger immediate risk in many scenarios is missing the mother's diagnosis. Radiation Risk in Pregnancy ACOG safety benchmark: No reported fetal harms have been documented below 50 mGy, a practical anchor for counseling when medically necessary imaging is on the table. Maternal risk perspective: Radiation risk is usually higher for the mother than the fetus, especially because developing breast tissue in pregnancy is more radiosensitive. ALARA without paralysis: As low as reasonably achievable still applies, but necessary CT, radiography, or nuclear imaging should not be withheld solely because a patient is pregnant. Everyday dose comparison: A standard chest x-ray is in the same ballpark as a transcontinental flight, and many common x-rays expose the fetus to even less radiation. Cancer risk framing: Radiation-related cancer risk is real but small; even higher-dose studies like pelvic CT still leave the overwhelming likelihood of no malignant consequence. We walk through a bedside way to say that out loud in the episode. Practical Imaging and Contrast Decisions Shared decision budget: Using a simple radiation budget built around the 50 mGy benchmark can make informed consent clearer and calm anxiety during PE or trauma imaging decisions. CT contrast in pregnancy: Iodinated IV contrast crosses the placenta, but human observational data have not shown teratogenicity or clinically important fetal thyroid harm. Gadolinium caution: Gadolinium is treated as potentially teratogenic and should be reserved for situations where it meaningfully improves the diagnostic performance of MRI. Breastfeeding after contrast: Both CT contrast and gadolinium are considered compatible with breastfeeding because only tiny amounts reach milk and even less is absorbed by the infant. Testing over avoidance: The key decision is whether the study is necessary, not whether it is perfectly risk-free; protecting maternal health is often the best way to protect the fetus. We get into the consent language in the chapter.

Lit Matters 1: Gestalt or Decision Tool?

Early sepsis recognition is still a bedside diagnosis as much as a score-driven one. In critically ill ED patients, experienced physician gestalt outperformed qSOFA, SOFA, SIRS, and MEWS in the first hour, while screening tools remained useful for subtler cases clinicians might otherwise miss. Sepsis Gestalt Versus Screening Tools Early bedside gestalt: Within 15 minutes of arrival, physician gestalt was the strongest early discriminator for sepsis, outperforming qSOFA, SOFA, SIRS, and MEWS in a high-acuity ED cohort. Fifteen-minute accuracy signal: The standout number was early accuracy in the low-80% range, a useful reminder that experienced clinicians often identify sepsis before formal scores fully declare themselves. MEWS specificity tradeoff: MEWS came closest on case capture but paid for it with more than 1,000 false positives, underscoring the classic sensitivity-versus-specificity problem in sepsis screening. One-hour reassessment window: By 60 minutes, all tools performed better, but physician visual-analog suspicion still led the pack. We get into why that timing matters in the episode. Experienced examiner effect: Most initial assessments were made by attending physicians, reinforcing that this study speaks most directly to practiced emergency clinicians using rapid pattern recognition at the bedside. Best blended approach: The practical takeaway is not scores versus clinicians but scores plus clinicians: gestalt appears best for early recognition, while structured tools may catch quieter sepsis presentations.

A Vascular Surgeon's Guide to AAA Rupture

Abdominal aortic aneurysm rupture is a time-critical cause of abdominal or back pain, shock, and sudden death. CT helps distinguish pending, contained, and frank rupture, while early ED management hinges on permissive hypotension, blood product support, and giving vascular surgery the few details that change the next move. Recognizing and Risk-Stratifying AAA Rupture Classic pain pattern: Ruptured AAA pain is typically sudden, severe, and described as wrapping from abdomen to back or back to abdomen, with little relief from position changes. High-risk exam clues: A palpable pulsatile mass, diaphoresis, tachycardia, hypotension, and even a sense of impending doom should push AAA rupture high on the differential. Atypical incidental discovery: Many AAAs surface on CT obtained for vague abdominal or low back pain rather than classic shock, so a deliberate image review matters. We get into the misses worth avoiding in the episode. Size-based rupture risk: In men, the risk of repair exceeds rupture risk when aneurysm diameter is under 5.5 cm, and a 4 cm AAA carries an annual rupture risk under 5%. CT rupture classification: CT separates pending rupture, contained rupture, and frank rupture; that classification rapidly frames both urgency and the likely operative path. ED Stabilization and Surgical Handoff Permissive hypotension target: For active AAA rupture, treat this as an aortic wall stress problem: keep blood pressure just high enough to maintain mentation rather than chasing normal vitals. Transfusion trigger points: Falling blood pressure, low hemoglobin, or frank contrast extravasation are strong signals to start blood products, often using a trauma-style massive transfusion approach. Consultant-critical history: Vascular surgery needs prior AAA history, any previous repair, exact pain onset and evolution, current vitals, and any sudden hemodynamic decline before they can plan next steps. Imaging transfer readiness: If the patient is moving to another facility, ensuring the CT images are immediately available can matter as much as the report itself. That workflow point is worth hearing in the chapter. Goals-of-care decision point: In frail patients or likely non-survivable rupture, early goals-of-care discussion may be more important than reflex transfer, because transport itself can consume their remaining time. Endovascular-first reality: Most ruptured AAAs are now repaired with an endovascular approach when anatomy provides an adequate landing zone, while unstable patients may first need balloon proximal control.

Making Sense of the 2023 Documentation Updates: Part 1

The 2023 ED E/M documentation update moved billing away from checkbox history and exam requirements and onto medical decision making. For emergency physicians, that means the note has to show problem complexity, data work, and management risk clearly enough for coding, handoffs, and medicolegal defense. 2023 ED E/M Documentation Changes MDM now drives billing: ED billing levels are now determined by medical decision making rather than counting HPI, ROS, or physical exam elements, a major shift from the old Marshfield-style checkbox approach. Lean history and exam: There is no billing requirement for a specific number of HPI, ROS, or exam elements, so the note can stay focused on clinically pertinent details that let others picture the patient. Combined note sections: HPI and ROS can effectively be merged for billing purposes, and past medical, social, and family history do not need separate sections if the relevant details are captured clearly. Two of three rule: The final E/M level comes from the highest 2 of 3 MDM categories: problem complexity, data reviewed, and management risk. We walk through how that changes charting priorities in the episode. Level mapping update: Straightforward through high MDM still map to ED visit levels, but 99281 has been removed from ER billing, narrowing the practical coding range to 99282 through 99285. Documenting Stronger MDM in the ED COPA reflects concern: Complexity of Problems Addressed is driven by the seriousness of the differential and the patient's context, so abdominal pain or fever on chemotherapy can support higher complexity than the final diagnosis suggests. Comorbidities belong in MDM: Document comorbidities and risk factors in the MDM, not just the HPI, so coders can see why those details matter to the current presentation and management choices. Either order or review: For a test from the current encounter, you get credit for ordering it or independently interpreting it, but not both; that either-or rule is one of the easiest places to lose points. Independent historian nuance: An independent historian must be someone other than the patient providing needed history for a justified reason; interpreters do not count because they relay rather than originate information. Considered but deferred tests: Documenting that you considered a test and appropriately did not order it, such as applying PECARN to defer pediatric head CT, can still count in the data section. That bedside wording is worth hearing in the chapter. Risk category anchors: Moderate risk includes prescription drug management and social determinants of health, while high risk includes decisions about hospitalization, toxic therapies, or major escalation and de-escalation choices.

Lit Matters 2: Evaluating the Evidence

Composite endpoints can hide as much as they reveal, and the win ratio is a prime example. This trial-analysis method is increasingly common in cardiology and MACE literature, but its apparent treatment effect can look stronger than the actual probability of benefit. Win Ratio in Clinical Trials Pairwise hierarchical comparisons: Win ratio matches one treated patient to one control patient, then compares them across a prespecified hierarchy such as death, heart failure events, and quality of life until one side records a win. Ties dropped from analysis: Pairs with no winner are excluded rather than counted as non-wins, a design choice that can materially inflate the apparent treatment effect when many patients have similar outcomes. Outcome ordering problem: The hierarchy is a researcher value judgment, and an early-tier event like death can be outweighed in the final headline by many late-tier wins from less important outcomes. We get into why that framing matters in the episode. Short-term versus long-term mixing: Win ratio can combine early symptomatic or biologic changes with later hard outcomes, making a treatment look broadly effective even when the signal is concentrated in short-term or surrogate measures. Seductive headline numbers: A reported win ratio of 1.36 can be misread as a 36% greater chance of benefit, when the actual win probability may be much closer to a single-digit absolute advantage. Retrospective use caution: The method is most defensible when the hierarchy is prospectively designed; retrospective win-ratio analyses are especially vulnerable to cherry-picked components and overstated conclusions. Misleading Trial Examples EMPULSE effect inflation: In EMPULSE, the published win ratio favored empagliflozin at 1.36, but the estimated win probability was only 58%, showing how the ratio can overstate the clinical impression. Ignored ties magnify benefit: When ties were treated as absences of wins rather than discarded, the apparent EMPULSE advantage dropped further to about 54%, underscoring how much the denominator matters. PARAGLIDE surrogate dominance: In PARAGLIDE, the headline advantage for sacubitril-valsartan was driven largely by natriuretic peptide changes, with roughly 36% of pairwise comparisons ending in ties. TRILUMINATE patient-reported skew: TRILUMINATE reported a win ratio of 1.48 favoring TEER, but much of that signal came from KCCQ improvement while heart failure hospitalizations actually leaned the other direction. Bottom-line appraisal: Win ratio is a potentially useful tool, but when lower-tier surrogate or symptom outcomes drive the wins, the final result may look more convincing than the long-term clinical benefit really is. That distinction is worth hearing in the chapter.

Making Sense of the 2023 Documentation Updates: Part 2

The 2023 ED E/M documentation rules shifted billing away from checkbox history and exam requirements and onto medical decision making. In emergency medicine, chart level now lives in COPA, data reviewed, and management risk, with the final level based on the highest 2 of 3 categories. 2023 ED E/M Documentation Changes MDM now drives billing: HPI, ROS, and physical exam no longer have minimum element counts for ED billing; chart level is determined by medical decision making rather than Marshfield-style box checking. Pertinent history still matters: A brief HPI can support a high-level chart if the MDM justifies it, but the note still needs enough clinical detail for coders and colleagues to mentally picture the patient. Focused exam is acceptable: There is no billing requirement for a full physical exam, yet a targeted organ-system exam remains clinically important for communication, risk framing, and medicolegal protection. Combined history workflow: HPI and ROS can be merged for billing purposes, and separate past, family, and social history sections are not required if the relevant details are captured where they matter. Critical care separate lane: If you are billing critical care, you do not also bill an E/M code, which prevents wasted effort trying to optimize both frameworks at once. We get into the practical implication in the episode. How to Score MDM Correctly Highest two categories rule: Final ED billing level is set by the highest 2 of 3 MDM domains: complexity of problems addressed, data reviewed, and risk of patient management. COPA favors clinical complexity: Complexity of Problems Addressed reflects the seriousness of the possibilities you are working through, not the eventual diagnosis; abdominal pain is a classic moderate-complexity presentation. Comorbidities belong in MDM: Document how chronic illness changes the current presentation in the MDM, because a chemotherapy patient with fever carries a very different risk signal than a healthy teenager. Either order or review: For a given test in the current encounter, you get credit for ordering it or reviewing/interpreting it, but not both; that either-or rule is one of the easiest places to overcount. Independent historian nuances: An independent historian must be someone other than the patient providing necessary history; interpreters do not count because they relay rather than originate information. We walk through the common edge cases in the chapter. Deferred test still counts: Documenting a considered but not ordered study can earn data credit when clinically justified, such as using PECARN to support not obtaining a pediatric head CT. Risk Documentation and Billing Pearls Prescription management counts: Moderate risk includes prescription drug management, and that category is broader than many realize, extending to parenteral medications and procedures like lidocaine injection. Social risk belongs here: Social determinants such as homelessness or limited transportation can support the risk element when they materially affect evaluation, treatment, or safe follow-up planning. High-risk management examples: High risk includes decisions about hospitalization, drug therapy requiring toxicity monitoring, and de-escalation of care because prognosis limits aggressive treatment. Interpretation versus separate billing: If your own EKG interpretation is what pushes the chart to a higher MDM level, folding it into the note may be smarter than billing a separate interpretation code. Useful coding reference: ERnotes.net is a free emergency medicine billing resource that helps translate the 2023 grid into usable documentation habits without defaulting back to template inflation.

Lit Matters 3: Defibrillation Strategies

Shock-refractory and recurrent ventricular fibrillation may respond better to alternative defibrillation than standard pad position alone. In out-of-hospital cardiac arrest, the strongest signal here favors double sequential external defibrillation after three failed shocks, while vector-change defibrillation looks less convincing. Refractory and Recurrent VF Defibrillation DSED survival signal: Double sequential external defibrillation showed the clearest improvement in survival to hospital discharge, with an overall adjusted odds ratio of 2.56 versus standard defibrillation. Recurrent VF indication: The benefit signal for DSED was not limited to shock-refractory VF; recurrent VF also appears to be a reasonable indication after early standard shocks fail, a practical nuance we get into in the episode. Vector change limits: Vector-change defibrillation improved VF termination more than standard shocks but did not show the same consistent survival advantage across primary and secondary outcomes. Three-shock decision point: After three initial defibrillation attempts with ongoing VF, escalating to a second defibrillator for DSED is a reasonable next move based on the DOSE-VF secondary analysis. Neurologically intact outcomes: In shock-refractory VF, standard defibrillation had no survivors to discharge in this cohort, while DSED produced neurologically intact survivors despite small numbers.